Status:
ACTIVE_NOT_RECRUITING
Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer
Lead Sponsor:
Kyungpook National University Hospital
Conditions:
Colon Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The main cause of recurrence after surgical treatment of colon cancer is distant metastasis. Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of chemotherapy. Preoperativ...
Eligibility Criteria
Inclusion
- Pathologically confirmed colon adenocarcinoma (\> 15 cm from the anal verge)
- Radiologic T3/T4 and high risk features by CT scan
- No metastasis on CT or PET(positron emission computed tomography)
- Age ≥ 18 and ≤ 70 years
- ECOG (Eastern Cooperative Oncology Group) performance status 0-1
- No history of colorectal cancer within 5 years
- No history of chemotherapy
- Patients with childbearing potential should use effective contraception during the study and the following 6 months
- Adequate bone marrow function : white blood cell count of 2 x 109/L or more with neutrophils of1.5 x 109/L or more, platelet count of 100 x 109/L or more, hemoglobin of 9 g/dL (5,6 mmol/l) or more
- Adequate hepatobiliary function : total bilirubin of 0.4 mg/dl or less, ASAT (aspartate aminotransferase) and ALAT (alanine aminotransferase) of 2.5 x ULN (upper limits of normal) or less, Alkaline phosphatase of 1.5 x ULN or less
- Adequate renal function : GFR (Glomerular Filtration Rate) \> 50ml/min by Wright or Cockcroft formula
- Signed written informed consent obtained prior to any study specific screening procedures
Exclusion
- Age \> 70 years and \< 18 years
- Rectal cancer : 15 cm or less from the anal verge
- Complicated colon cancer (complete obstruction, perforation, bleeding)
- Metastatic colon cancer
- Known hypersensitivity reaction to any of the components of study treatments
- Inflammatory bowel disease
- Hereditary nonpolyposis colorectal cancerHNPCC, familial Adenomatous Polyposis
- Clinically relevant coronary artery disease or history of myocardial infarction in the last 6 months, high risk of uncontrolled arrhythmia
- Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
- Pregnancy or breast-feeding period
- Serious non-healing wound or bone fracture
- Medical, geographical, sociological, psychological or legal conditions that would not permit the patient to complete the study or sign informed consent
- Any significant disease which, in the investigator's opinion, would exclude the patient from the study
Key Trial Info
Start Date :
October 24 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 28 2030
Estimated Enrollment :
708 Patients enrolled
Trial Details
Trial ID
NCT03426904
Start Date
October 24 2018
End Date
December 28 2030
Last Update
March 5 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Chonnam National University Hwasun Hospital
Hwasun, Chonnam, South Korea, 58128
2
Kyungpook National University Chilgok Hospital
Daegu, South Korea, 41404
3
Asan Medical Center
Seoul, South Korea, 05505
4
The Catholic Univ. of Korea St. Vincent's Hospital
Suwon, South Korea